CD30, also known as TNFRSF8 (TNF receptor superfamily member 8), [5] is a cell membrane protein of the tumor necrosis factor receptor family and a tumor marker. This receptor is expressed by activated, but not by resting, T and B cells.

CD30, also known as BerH2, Ki1 or TNFRSF8, is a transmembrane glycoprotein receptor that belongs to the tumor necrosis factor receptor (TNFR) and was first identified in Hodgkin lymphoma cell lines but also expressed in normal activated B and T cells.

Sep 8, 2017 · CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma...

CD30, also known as TNFRSF8 (tumor necrosis factor receptor superfamily member 8), is a protein receptor that is heavily glycosylated inside the Golgi apparatus, as well as a tumor marker that is found on the surface of specific cells in the body, …

Cluster determinant 30 (CD30) has been recognized since the 1980s by a monoclonal antibody (Ki-1) as an epitope of a membrane protein highly expressed on Reed–Sternberg and Hodgkin’s lymphoma cells [9 – 11] and infrequently on normal blood lymphocytes.

CD30, a member of the tumor necrosis factor receptor superfamily, plays roles in pro-survival signal induction and cell proliferation in peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia/lymphoma (ATL).

CD30 was originally described as a marker of Hodgkin's and Reed-Sternberg cells in Hodgkin's lymphoma. Cloning and characterization of cDNAs encoding CD30 and its ligand (CD30L) established these proteins as members of the tumor necrosis factor receptor (TNFR) and tumor necrosis factor (TNF) superfa …

CD30 is a cell surface receptor expressed in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), and many other lymphomas to a variable degree. It has been identified as an important therapeutic target in lymphoma.

May 20, 2012 · CD30 is the target of brentuximab vedotin (Adcetris), an antibody drug conjugate (ADC) that is approved for the treatment of patients with relapsed HL and systemic ALCL after failure of other therapies.

CD30 refers to a TNFR-related surface protein that is expressed by activated T and B cells. It was originally identified as a marker for the tumor cells of Hodgkin's lymphoma. CD30 has also been found on other types of tumors, and a soluble form of CD30 has been detected at high levels in the serum of patients with certain autoimmune diseases.